Table 1.

Detailed list of patients

Case	Gender	Affected eye	Reduction rate (%)	Highest IOP (mmHg)	Pre Treat VA (log MAR)	Final MD (dB)	PCR	Ope
1	M	L	-1.5	31	-0.1	NP	−	−
2	F	R	4.4	35	0.1	NP	−	−
3	F	R	7	14	-0.1	−0.32	−	−
4	F	R	9.7	27	0.2	NP	−	−
5	M	L	15.6	19	1	GP	−	−
6	M	R	21.8	23	−0.2	-8.33	CMV	−
7	F	R	43.8	46	0.1	−0.4	−	−
8	F	R	4.9	42	−0.1	−1.37	−	−
9	M	R	72.7	26	0	−0.28	−	−
10	M	R	8.3	43	−0.2	−1.43	−	−
11	F	L	2.2	49	−0.1	−0.46	−	−
12	F	L	17.6	26	−0.2	0.8	−	−
13	M	R	9.1	68	0.4	−28.38	−	+
14	F	L	23.3	68	−0.2	-6.45	CMV	+
15	M	R	23.9	68	−0.1	−4.38	−	+
16	F	R	25	68	0.3	−2.2	−	+
17	M	R	31.9	68	0	−4.76	−	+
18	M	R	31.9	68	0.1	−7.4	−	+
19	M	L	31.6	68	-0.1	GP	−	+
20	F	L	40.8	68	-0.1	1.67	Parvo B19	+
21	F	L	59.6	68	0	−5.25	−	+
22	F	L	74.6	68	0.5	−6.31	−	+
23	F	R	7.8	68	0	−16.9	−	+
24	M	R	32.6	68	0	-6.17	CMV	+
25	M	R	4.4	68	−0.2	−26.27	−	+
26	F	R	28	68	0	-19.82	CMV	+
27	M	R	8.8	68	0.5	-30.85	CMV	+
28	M	L	45.6	42	−0.2	−27.65	−	+
29	F	L	64.7	42	−0.1	-6.57	CMV	+
30	M	L	9.7	34	0.2	-24.98	CMV	+
31	M	R	25.3	44	−0.2	−14.16	−	+
32	M	R	62.3	46	0	17.34	−	+
33	M	L	26	43	0.4	−22.478	−	+

IOP intraocular pressure; VA visual acuity; MD mean deviation; M male; F female; NP not performed; GP Goldmann perimetry; CMV cytomegalovirus; TLE trabeculectomy; TLO trabeculotomy; TTO trabecutome